Tarpeyo is a drug owned by Calliditas, primarily used in the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression. It consists of budesonide as its active ingredient and is available in capsule, delayed release; oral dosage forms. Tarpeyo was first authorized for market use on 15th December 2021.
The generic version of Tarpeyo could potentially be released after the 7th of May 2029. This date is contingent on the expiration of the drug's current patent (US8491932), which is set to expire on the same day.
Tarpeyo contains budesonide, which plays a significant role in its use as a treatment for primary immunoglobulin A nephropathy (IgAN) in adults. This is especially pertinent for individuals at risk of rapid disease progression.
Tarpeyo holds a total of 1 drug patent, US8491932, regarding 'Compositions for the oral delivery of corticosteroids.' The patent is slated to expire on May 7, 2029, thereby setting a potential release date for Tarpeyo's generic version. Below are the details of the patent: